



ABN 53 075 582 740

ASX ANNOUNCEMENT

5 June 2019

BNC375 Medicinal Chemistry Paper Published in International Peer-Reviewed Journal

Bionomics Limited (ASX: BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today announced that a paper describing the generation of the novel class of compounds which led to the discovery on BNC375 has been published in the scientific journal, **ACS Medicinal Chemistry Letters**.

ACS Medicinal Chemistry Letters is a peer-reviewed academic journal in the field of medicinal chemistry. The journal was founded in 2009 and is published monthly by the American Chemical Society.

The paper *Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of $\alpha 7$ nAChRs*, is authored by chemists and biologists from Bionomics and its subsidiary companies in Europe; Neurofit SAS and Prestwick Chemical and published on March 25, 2019.

The novel series of compounds described in the paper comprises allosteric modulators of the Alpha 7 Nicotinic Acetylcholine Receptor (nAChR) targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. BNC375 is the lead compound of the series.

Bionomics' BNC375 research program initiated the exclusive Research Collaboration and License Agreement between Bionomics and Merck & Co., Inc., Kenilworth, NJ USA (known as MSD outside the United States and Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications

Rudi Michelson

+613 9620 3333

rudim@monsoon.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of agitation, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210), its licensing agreements with Merck & Co. Inc., Kenilworth, NJ, USA and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.